ImmunoPrecise To Acquire U-Protein and Announces $4,000,000 Financing
Victoria, British Columbia, Canada, July 4, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with U-Protein Express BV (“U-Protein“) whereby the Company has agreed to acquire all of the issued and outstanding shares of U-Protein (the “Transaction”). This represents a key step in the... Read more